Paul Mayor
Gynecologic Oncology · Jonesboro, GANPI 1851685838
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $1,950 of the $2,398 with a category attached, or 81.3%. Johnson & Johnson accounts for 83.5% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2021 at $1,971 and has fallen 93.9% since, to $121 in 2024. That places this record below the midpoint for gynecologic oncology clinicians in GA, where the typical reported total is $3,080.
Across 8 payments — averaging $299.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Mimedx Group, Inc.$121
- Clovis Oncology, Inc.$105
- Foundation Medicine, Inc.$105
- Puma Biotechnology, Inc.$28
- Intuitive Surgical$21
- plus $17 from 1 others
Across 21 payments — averaging $24,302 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$326K
- Merck$151K
- Karyopharm Therapeutics Inc.$34K
What the payments were for
- Consulting fees$1,95081%
- Food & beverage$44819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $2,003 |
| Mimedx Group, Inc. | 1 | $121 |
| Clovis Oncology, Inc. | 1 | $105 |
| Foundation Medicine, Inc. | 1 | $105 |
| Puma Biotechnology, Inc. | 1 | $28 |
| Intuitive Surgical | 1 | $21 |
| AstraZeneca | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STRATAFIX$1,950
- SURGICEL NU-KNIT$1,950
- SURGIFLO Hemostatic Matrix$1,950
- VISTASEAL$1,950
- Rubraca$105
- FOUNDATIONONE$105
- FOUNDATIONONE HEME$105
- FOUNDATIONONE CDX$105
- FOUNDATIONFOCUS$105
- FOUNDATIONONE LIQUID$105
How this compares
$2,398 in reported general payments places this provider in the 40th percentile of 49 gynecologic oncology providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 22 | $367,010 |
| Dexamethasone | 39 | $451 |
| Ibuprofen | 39 | $335 |
| Ondansetron OdtOndansetron | 35 | $302 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 26 | $258 |
| Olanzapine | 24 | $158 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $17 | $367,01022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 49 gynecologic oncology providers in Georgia.
Other gynecologic oncology in Jonesboro
- James BurkeSavannah$276K
- Benedict BenignoAtlanta$273K
- Sharad GhamandeAugusta$214K
- Ruchi GargNewnan$125K
- Adam PyrzakAtlanta$116K
- Gerald FeuerAtlanta$102K
- Margarett EllisonMoultrie$81K
- Vijaya GalicGainesville$35K
- Guilherme CantuariaAtlanta$13K
- Mitzie-Ann DavisFayetteville$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.